title: Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression.
abstract: Numerous studies have shown that long non-coding RNAs (lncRNAs) behave as a novel class of transcript during multiple cancer processes, such as cell proliferation, apoptosis, migration, and invasion. LINC00152 is located on chromosome 2p11.2, and has a transcript length of 828 nucleotides. The biological role of LINC00152 in LAD(lung adenocarcinoma) remains unknown.
  
  
  
  Quantitative reverse transcription PCR(qRT-PCR) was used to detect LINC00152 expression in 60 human LAD tissues and paired normal tissues. In vitro and in vivo studies showed the biological function of LINC00152 in tumour progression. RNA transcriptome sequencing technology was performed to identify the downstream suppressor IL24(interleukin 24) which was further examined by qRT-PCR, western bolt and rescue experiments. RNA immunoprecipitation (RIP), RNA pulldown, and Chromatin immunoprecipitation (ChIP) assays were carried out to reveal the interaction between LINC00152, EZH2 and IL24.
  
  
  
  LINC00152 expression was upregulated in 60 human LAD tissues and paired normal tissues. High levels of LINC00152 expression were correlated with advanced TNM stage, larger tumor size, and lymph node metastasis, as well as shorter survival time. Silencing of LINC00152 suppressed cell growth and induced cell apoptosis. LINC00152 knockdown altered the expression of many downstream genes, including IL24. LINC00152 could interact with EZH2 and inhibit IL24 transcription. Moreover, the ectopic expression of IL24 repressed cell proliferation and partly reversed LINC00152 overexpression-induced promotion of cell growth in LAD.
  
  
  
  Our study reveals an oncogenic role for LINC00152 in LAD tumorigenesis, suggesting that it could be used as a therapeutic target in LAD treatment.
authors.affiliation: Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, People's Republic of China.
authors.forename: Qin-Nan
authors.initials: QN
authors.lastname: Chen
authors.affiliation: Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, People's Republic of China.
authors.forename: Xin
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, People's Republic of China.
authors.forename: Zhen-Yao
authors.initials: ZY
authors.lastname: Chen
authors.affiliation: Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, People's Republic of China.
authors.forename: Feng-Qi
authors.initials: FQ
authors.lastname: Nie
authors.affiliation: Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, People's Republic of China.
authors.forename: Chen-Chen
authors.initials: CC
authors.lastname: Wei
authors.affiliation: Department of Pathology, First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
authors.forename: Hong-Wei
authors.initials: HW
authors.lastname: Ma
authors.affiliation: Department of Oncology, Huai'an First People's Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
authors.forename: Li
authors.initials: L
authors.lastname: Wan
authors.affiliation: Department of Oncology, The Affiliated Jiangyin Hospital Of Southeast University Medical College, Jiangyin, China.
authors.forename: Shuai
authors.initials: S
authors.lastname: Yan
authors.affiliation: Department of Oncology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
authors.forename: Sheng-Nan
authors.initials: SN
authors.lastname: Ren
authors.affiliation: Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, 210011, People's Republic of China. zhaoxiawang88@126.com.
authors.forename: Zhao-Xia
authors.initials: ZX
authors.lastname: Wang
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D016000:Cluster Analysis; D019295:Computational Biology / Q000379:methods; D004195:Disease Models, Animal; D000066630:Ectopic Gene Expression; D000071221:Enhancer of Zeste Homolog 2 Protein / Q000235:genetics*; D005260:Female; D059585:G1 Phase Cell Cycle Checkpoints / Q000235:genetics; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D056466:Histone Demethylases / Q000235:genetics; D006801:Humans; D007378:Interleukins / Q000235:genetics*; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D051379:Mice; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D034622:RNA Interference; D062085:RNA, Long Noncoding / Q000235:genetics*; D047368:Tumor Burden; D000099180:Interleukin-24
chemical_list: D000071221:Enhancer of Zeste Homolog 2 Protein; D056466:Histone Demethylases; D007378:Interleukins; D062085:RNA, Long Noncoding; D000099180:Interleukin-24; C495195:KDM1A protein, human; C498409:EZH2 protein, human
keywords: IL24; LINC00152; Long intergenic non-coding RNA; Lung adenocarcinoma; Proliferation